Waiv, formerly Owkin Dx, to leverage its digital pathology platform encompassing foundation models and AI methodology for ADC biomarker discovery program

Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program.

With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solutions across the full drug development lifecycle.

Under the collaboration, Waiv will apply its end-to-end computational pathology platform to early phase data. This includes tumor microenvironment (TME) analysis across both hematoxylin and eosin (H&E) and immunohistochemistry (IHC) stained samples, as well as biomarker discovery and outcome prediction capabilities aimed at identifying biomarkers of treatment response ahead of next clinical trial phases.

Purpose-built AI approach tackles one of pharma's hardest challenges: biomarker discovery in less than 100 patients for ADC medicines.

Waiv's computational pathology platform is designed specifically for data-constrained settings, underpinned by a suite of foundation models developed across hundreds of thousands of images from its international data network. Its approach combines:

Developing bespoke AI models optimized for low-data environments
Extracting predictive signals directly from whole slide images across H&E and IHC stained samples
Identifying novel histopathological biomarkers beyond predefined features
Delivering reproducible, interpretable outputs suitable for clinical decision-making

"Identifying which patients will respond to a therapy directly from the pathology slide is simultaneously one of the hardest problems and one of the most important opportunities in oncology drug development. It is exactly what we’ve built Waiv to deliver," said Meriem Sefta, CEO and Co-Founder, Waiv. "This collaboration with Daiichi Sankyo reflects our ability to engage early and take biomarkers all the way through to clinically validated, deployable tests. That end-to-end capability is what makes us valuable long-term collaborators."

View source version on businesswire.com: https://www.businesswire.com/news/home/20260506435046/en/

Media Inquiries:
Waiv: rajin.kang-ext@wearewaiv.com
marketing@wearewaiv.com

Logo

Tags

More Like This

Waiv Secures $33 Million to Scale AI Precision Testing

Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing

Waiv Achieves Dual CE Marking Under IVDR, Propelling AI Precision Testing for Breast and Colorectal Cancer for Clinical Routine

Discovery Life Sciences and Mindpeak Partner to Bring AI Precision to Cancer Biomarker Testing in Global Clinical Trials

Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery

Owkin enters collaboration agreement with MSD to develop AI-powered diagnostics for cancer

Owkin unveils new insights into the opportunities and challenges for digital pathology and AI solutions in healthcare

Owkin's Specialized Biological AI Agent Pathology Explorer Launches with Anthropic's Claude for Healthcare and Life Sciences